These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Increased serum levels of tumour-associated trypsin inhibitor independently predict a poor prognosis in colorectal cancer patients. Gaber A; Nodin B; Hotakainen K; Nilsson E; Stenman UH; Bjartell A; Birgisson H; Jirström K BMC Cancer; 2010 Sep; 10():498. PubMed ID: 20849596 [TBL] [Abstract][Full Text] [Related]
4. Tumour-associated trypsin inhibitor TATI is a prognostic marker in colorectal cancer. Koskensalo S; Hagström J; Louhimo J; Stenman UH; Haglund C Oncology; 2012; 82(4):234-41. PubMed ID: 22508321 [TBL] [Abstract][Full Text] [Related]
5. Tumour-associated trypsin inhibitor, carcinoembryonic antigen and acute-phase reactant proteins CRP and alpha1-antitrypsin in patients with gastrointestinal malignancies. Solakidi S; Dessypris A; Stathopoulos GP; Androulakis G; Sekeris CE Clin Biochem; 2004 Jan; 37(1):56-60. PubMed ID: 14675563 [TBL] [Abstract][Full Text] [Related]
6. Expression of trypsinogen-1, trypsinogen-2, and tumor-associated trypsin inhibitor in ovarian cancer: prognostic study on tissue and serum. Paju A; Vartiainen J; Haglund C; Itkonen O; von Boguslawski K; Leminen A; Wahlström T; Stenman UH Clin Cancer Res; 2004 Jul; 10(14):4761-8. PubMed ID: 15269150 [TBL] [Abstract][Full Text] [Related]
7. Tumor-associated trypsin inhibitor (TATI) in patients with colorectal carcinoma. A critical comparison with CEA. Catarino M; Conde R Scand J Clin Lab Invest Suppl; 1991; 207():43-6. PubMed ID: 1780689 [TBL] [Abstract][Full Text] [Related]
8. Postoperative CEA is a better prognostic marker than CA19-9, hCGβ or TATI after resection of colorectal liver metastases. Peltonen R; Österlund P; Lempinen M; Nordin A; Stenman UH; Isoniemi H Tumour Biol; 2018 Jan; 40(1):1010428317752944. PubMed ID: 29378497 [TBL] [Abstract][Full Text] [Related]
9. Effects of radiation therapy on tissue and serum concentrations of tumour associated trypsin inhibitor and their prognostic significance in rectal cancer patients. Gaber A; Stene C; Hotakainen K; Nodin B; Palmquist I; Bjartell A; Stenman UH; Jeppsson B; Johnson LB; Jirström K Radiat Oncol; 2011 Aug; 6():100. PubMed ID: 21864386 [TBL] [Abstract][Full Text] [Related]
10. Serum tumour associated trypsin inhibitor, as a biomarker for survival in renal cell carcinoma. Tornberg SV; Nisen H; Järvinen P; Järvinen R; Kilpeläinen TP; Taari K; Stenman UH; Visapää H Scand J Urol; 2020 Oct; 54(5):413-419. PubMed ID: 32748674 [TBL] [Abstract][Full Text] [Related]
11. Concomitant tumor expression of EGFR and TATI/SPINK1 associates with better prognosis in colorectal cancer. Koskensalo S; Louhimo J; Hagström J; Lundin M; Stenman UH; Haglund C PLoS One; 2013; 8(10):e76906. PubMed ID: 24204699 [TBL] [Abstract][Full Text] [Related]
12. The Relationship between the Tissue Expression of TLR2, TLR4, TLR5, and TLR7 and Systemic Inflammatory Responses in Colorectal Cancer Patients. Beilmann-Lehtonen I; Hagström J; Kaprio T; Stenman UH; Strigård K; Palmqvist R; Gunnarsson U; Böckelman C; Haglund C Oncology; 2021; 99(12):790-801. PubMed ID: 34515203 [TBL] [Abstract][Full Text] [Related]
13. Tumour-associated trypsin inhibitor (TATI) in patients with colorectal cancer: a comparison with CEA, CA 50 and CA 242. Pasanen P; Eskelinen M; Kulju A; Penttilä I; Janatuinen E; Alhava E Scand J Clin Lab Invest; 1995 Apr; 55(2):119-24. PubMed ID: 7667604 [TBL] [Abstract][Full Text] [Related]
14. Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer. The RANX05 Colorectal Cancer Study Group. Nielsen HJ; Christensen IJ; Sørensen S; Moesgaard F; Brünner N Ann Surg Oncol; 2000 Sep; 7(8):617-23. PubMed ID: 11005561 [TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of tumor-associated trypsin inhibitor (TATI) and human chorionic gonadotropin-β (hCGβ) in patients with hepatocellular carcinoma. Lyytinen I; Lempinen M; Nordin A; Mäkisalo H; Stenman UH; Isoniemi H Scand J Gastroenterol; 2013 Sep; 48(9):1066-73. PubMed ID: 23889187 [TBL] [Abstract][Full Text] [Related]
16. Prognostic value of the combined expression of tumor-associated trypsin inhibitor (TATI) and p53 in patients with bladder cancer undergoing radical cystectomy. Liu A; Xue Y; Liu F; Tan H; Xiong Q; Zeng S; Zhang Z; Gao X; Sun Y; Xu C Cancer Biomark; 2019; 26(3):281-289. PubMed ID: 31594208 [TBL] [Abstract][Full Text] [Related]
17. High expression of tumour-associated trypsin inhibitor correlates with liver metastasis and poor prognosis in colorectal cancer. Gaber A; Johansson M; Stenman UH; Hotakainen K; Pontén F; Glimelius B; Bjartell A; Jirström K; Birgisson H Br J Cancer; 2009 May; 100(10):1540-8. PubMed ID: 19384300 [TBL] [Abstract][Full Text] [Related]
18. Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer. Kwon KA; Kim SH; Oh SY; Lee S; Han JY; Kim KH; Goh RY; Choi HJ; Park KJ; Roh MS; Kim HJ; Kwon HC; Lee JH BMC Cancer; 2010 May; 10():203. PubMed ID: 20465852 [TBL] [Abstract][Full Text] [Related]
19. Biology and function of tumor-associated trypsin inhibitor, TATI. Stenman UH; Koivunen E; Itkonen O Scand J Clin Lab Invest Suppl; 1991; 207():5-9. PubMed ID: 1780691 [TBL] [Abstract][Full Text] [Related]
20. Serum Serine Peptidase Inhibitor Kazal-Type 1, Trypsinogens 1 to 3, and Complex of Trypsin 2 and α1-Antitrypsin in the Diagnosis of Severe Acute Pancreatitis. Rainio M; Lindström O; Penttilä A; Itkonen O; Kemppainen E; Stenman UH; Kylänpää L Pancreas; 2019 Mar; 48(3):374-380. PubMed ID: 30747826 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]